Marché nord-américain du diagnostic des tissus cancéreux jusqu’en 2027 – Analyse régionale et prévisions par type de test (tests immunohistochimiques et tests d’hybridation in situ) et pays

Historic Data: 2016-2017   |   Base Year: 2018   |   Forecast Period: 2019-2027


No. of Pages: 132    |    Report Code: TIPRE00006459    |    Category: Life Sciences

North America Cancer Tissue Diagnostics Market

Le marché nord-américain du diagnostic des tissus cancéreux devrait atteindre 1 587,38 millions de dollars américains en 2027, contre 923,79 millions de dollars américains en 2018. Le marché devrait croître avec un TCAC de 6,5 % par rapport à 2019-2027.

 

La croissance du marché est tirée par des facteurs tels que,  prévalence croissante du cancer dans la région nord-américaine et lancements et développements de nouveaux produits Approbations FDA. Cependant, le marché devrait ralentir sa croissance en raison du manque de politiques de remboursement pour le diagnostic du cancer dans la région.

 

Fréquents FDA les approbations et les lancements de produits alimentent la croissance du marché du diagnostic des tissus cancéreux. La plupart des principaux acteurs du marché sont impliqués dans la fabrication d’une large gamme de produits de diagnostic du cancer offrant un maximum d’avantages et un diagnostic précoce. Par exemple, en juin 2019, Agilent Technologies Inc. a reçu l’approbation de la Food and Drug Administration (FDA) des États-Unis pour son test PD-L1 IHC 22C3 pharmDx. Le test est approuvé pour viser à identifier les patients atteints d\'un carcinome épidermoïde de la tête et du cou (HNSCC) pour un traitement par KEYTRUDA (pembrolizumab), un traitement anti-PD-1 fabriqué par Merck. De plus, en mars 2018, Agilent Technologies Inc. a lancé une nouvelle couleur pour l\'immunohistochimie : HRP Magenta pour Dako Omnis. Les dernières caractéristiques de coloration du chromogène l’aideront à évaluer les tissus cutanés et pulmonaires. Ainsi, les développements constants de la technologie en matière de diagnostic ainsi que les approbations de la FDA accélèrent la croissance du marché au cours de la période de prévision.

 

Les États-Unis devraient dominer le marché dans la région Amérique du Nord en raison de la prévalence croissante du cancer, de l’amélioration du diagnostic et du traitement de la maladie ainsi que des progrès réalisés par les acteurs du marché. De plus, le pays compte plusieurs hôpitaux, des hôpitaux super spécialisés qui offrent des services de diagnostic et de traitement des maladies cardiovasculaires. Par conséquent, compte tenu des facteurs mentionnés ci-dessus, la croissance du marché dans le pays contribuera probablement à la plus grande part de la région Amérique du Nord au cours de la période de prévision.

 

 


DIAGNOSTIC DES TISSUS DU CANCER EN AMÉRIQUE DU NORD - SEGMENTATION DU MARCHÉ


Par type de test

  • Tests immunohistochimiques
    • Cancer du sein
    • Cancer colorectal
    • Cancer de la prostate
    • Cancer de l\'estomac
    • Autres
  • Tests d\'hybridation in situ
    • Cancer du sein
    • Cancer du poumon
    • < span>Cancer de la vessie
    • Autres

 

Profils d\'entreprises

  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc.
  • Bio Rad Laboratories Inc.
  • Abbott
  • Enzo Life Sciences, Inc.
  • Agilent Technologies, Inc.
  • Cancer Genetics Inc.
  • Merck KGaA (Sigma-Aldrich Co. LLC)
  • Danaher Corporation
  • Abcam plc


North America Cancer Tissue Diagnostics Strategic Insights

Strategic insights for North America Cancer Tissue Diagnostics involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/north-america-cancer-tissue-diagnostics-market-strategic-framework.webp
Get more information on this report

North America Cancer Tissue Diagnostics Report Scope

Report Attribute Details
Market size in 2018 US$ 923.79 Million
Market Size by 2027 US$ 1,587.38 Million
Global CAGR (2019 - 2027) 6.5%
Historical Data 2016-2017
Forecast period 2019-2027
Segments Covered By Type de test
  • tests immunohistochimiques et tests d\'hybridation in situ
Regions and Countries Covered Amérique du Nord
  • États-Unis
  • Canada
  • Mexique
Market leaders and key company profiles
  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc.
  • Bio Rad Laboratories Inc.
  • Abbott
  • Enzo Life Sciences, Inc.
  • Agilent Technologies, Inc.
  • Cancer Genetics Inc.
  • Merck KGaA (Sigma-Aldrich Co. LLC)
  • Danaher Corporation
  • Abcam plc
  • Get more information on this report

    North America Cancer Tissue Diagnostics Regional Insights

    The regional scope of North America Cancer Tissue Diagnostics refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/north-america-cancer-tissue-diagnostics-market-geography.webp
    Get more information on this report

    The List of Companies - North America Cancer Tissue Diagnostics Market

    The List of Companies

    1. F. Hoffmann-La Roche Ltd
    2. Thermo Fisher Scientific Inc.
    3. Bio Rad Laboratories Inc.
    4. Abbott
    5. Enzo Life Sciences, Inc.
    6. Agilent Technologies, Inc.
    7. Cancer Genetics Inc.
    8. Merck KGaA (Sigma-Aldrich Co. LLC)
    9. Danaher Corporation
    10. Abcam plc

     

    Frequently Asked Questions
    How big is the North America Cancer Tissue Diagnostics Market?

    The North America Cancer Tissue Diagnostics Market is valued at US$ 923.79 Million in 2018, it is projected to reach US$ 1,587.38 Million by 2027.

    What is the CAGR for North America Cancer Tissue Diagnostics Market by (2019 - 2027)?

    As per our report North America Cancer Tissue Diagnostics Market, the market size is valued at US$ 923.79 Million in 2018, projecting it to reach US$ 1,587.38 Million by 2027. This translates to a CAGR of approximately 6.5% during the forecast period.

    What segments are covered in this report?

    The North America Cancer Tissue Diagnostics Market report typically cover these key segments-

  • Type de test (tests immunohistochimiques et tests d\'hybridation in situ)
  • What is the historic period, base year, and forecast period taken for North America Cancer Tissue Diagnostics Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Cancer Tissue Diagnostics Market report:

  • Historic Period : 2016-2017
  • Base Year : 2018
  • Forecast Period : 2019-2027
  • Who are the major players in North America Cancer Tissue Diagnostics Market?

    The North America Cancer Tissue Diagnostics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc.
  • Bio Rad Laboratories Inc.
  • Abbott
  • Enzo Life Sciences, Inc.
  • Agilent Technologies, Inc.
  • Cancer Genetics Inc.
  • Merck KGaA (Sigma-Aldrich Co. LLC)
  • Danaher Corporation
  • Abcam plc
  • Who should buy this report?

    The North America Cancer Tissue Diagnostics Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the North America Cancer Tissue Diagnostics Market value chain can benefit from the information contained in a comprehensive market report.